Herting, Cameron J. http://orcid.org/0000-0002-4937-8392
Farren, Matthew R.
Tong, Yan
Liu, Ziyue
O’Neil, Bert
Bekaii-Saab, Tanios
Noonan, Anne
McQuinn, Christopher
Mace, Thomas A.
Shaib, Walid
Wu, Christina
El-Rayes, Bassel F.
Shahda, Safi
Lesinski, Gregory B.
Funding for this research was provided by:
Merck
National Cancer Institute (P30CA138292)
Article History
Received: 14 December 2020
Accepted: 11 June 2021
First Online: 23 June 2021
Declarations
:
: MRF, CJH, YT, ZL, AN, CM, and TAM have no conflicts of interest to declare. BO has consulted for Genentech, Amgen, and Merck. The terms of these arrangements have been reviewed and approved by Indiana University in accordance with its conflict-of-interest policies. TBS has consulted for Ipsen, Array Biopharma, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, and Merck through his institution. TBS has also consulted for Boehringer Ingelheim, Janssen, Eisai, Daichii Sankyo, Natera, TreosBio, Celularity, Exact Science, and Sobi and has been compensated for these services. TBS has received research funding from Agios, Arys, Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Array Biopharma, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and BMS. The terms of these arrangements have been reviewed and approved by Mayo Clinic in accordance with their conflict-of-interest policies. WS has received honoraria from Merck, BMS, Lexicon, Mylan, Ipsen, Blueprint Medicine, Signatera, and Exilexis. Dr. Shaib has also received research support from Lexicon, Eli Lilly, and GSK. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. CW has consulted for Natera and Array Biopharma as well as received clinical trial funding from Vaccinex, Rapt Therapeutics, INBHRX, Boston Biomedical Inc., Seattle Genetics, Lycera, and Symphogen. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. BFE has consulted for Ipsen, Merck and Co., Bayer, AstraZeneca, Bristol-Myers Squibb, Inc. and been a speaker for Lexicon, Inc. He serves as a consultant to Merck and Co., and receives compensation for these services. He has also received research funding through a sponsored research agreement between Emory University and Bristol-Myers Squibb, Boston Biomedical, Novartis, Merck and Co, Bayer, Exelixis, Pfizer, AstraZeneca/Medimmune, Incyte, and EUSA. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. SS is currently employed by Eli Lilly. GBL has consulted for ProDa Biotech, LLC and received compensation. He has also received research funding through a sponsored research agreement between Emory University and Merck and Co., Bristol-Myers Squibb, Boerhinger-Ingelheim, and Vaccinex. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies.
: All authors and relevant funding sources have read and approved the final version of this manuscript and consent its publication.
: This study was conducted in accordance with the IRB procedures at Emory University (IRB00080442), Indiana University (1502701251), and The Ohio State University and was approved by their Ethics Boards. All patients were consented prior to participation in this trial (NCT02375672).This study was conducted in accordance with the IRB procedures at Emory University (IRB00080442), Indiana University (1502701251), and The Ohio State University and was approved by their Ethics Boards. All patients were consented prior to participation in this trial (NCT02375672).